Guerbet: Financial agenda for 2024
15 Jan 2024
Financial Statement
Guerbet: Financial agenda for 2024
Financial agenda for 2024
Villepinte, 15 January 2024: Guerbet (FR0000032526), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2024.
Publications calendar
2023 ANNUAL REVENUE
February 08, 2024, after trading
2023 ANNUAL RESULTS
March 20, 2024, after trading
2024 1ST QUARTER REVENUE
April 25, 2024, after trading
ANNUAL SHAREHOLDERS’ MEETING
May 24, 2024
2024 2ND QUARTER REVENUE
July 25, 2024, after trading
2024 FIRST HALF RESULTS
September 25, 2024, after trading
2024 3RD QUARTER REVENUE
October 24, 2024, after trading
About Guerbet
At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 95 years, with more than 2,600 employees worldwide, we continuously innovate and devote 10% of our sales to research and development in four centres in France, Israel, and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €753 million in revenue in 2022.
Contacts :
Guerbet
Jérôme Estampes, Chief Financial Officer + 33.1.45.91.50.00 / jerome.estampes@guerbet.com
Claire Lauvernier, Group Communication Director +33.6.79.52.11.88 / claire.lauvernier@guerbet.com
Actifin
Marianne Py, Financial Communication + 33.1.80.48.25.31 / marianne.py@seitosei-actifin.com
Jennifer Jullia, Media Relations +33.1.56.88.11.19 / jennifer.jullia@seitosei-actifin.com
Attachment
Guerbet_PR Agenda 2024
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.